JP2017509623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509623A5 JP2017509623A5 JP2016556270A JP2016556270A JP2017509623A5 JP 2017509623 A5 JP2017509623 A5 JP 2017509623A5 JP 2016556270 A JP2016556270 A JP 2016556270A JP 2016556270 A JP2016556270 A JP 2016556270A JP 2017509623 A5 JP2017509623 A5 JP 2017509623A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition according
- hpo
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 16
- 239000011734 sodium Substances 0.000 claims 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 229910019142 PO4 Inorganic materials 0.000 claims 9
- 239000010452 phosphate Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 8
- 229910052708 sodium Inorganic materials 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 239000000872 buffer Substances 0.000 claims 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 5
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 5
- 235000019800 disodium phosphate Nutrition 0.000 claims 5
- 239000008363 phosphate buffer Substances 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims 3
- 239000012458 free base Substances 0.000 claims 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims 3
- 208000029028 brain injury Diseases 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 235000011008 sodium phosphates Nutrition 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 239000004254 Ammonium phosphate Substances 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims 1
- 235000019289 ammonium phosphates Nutrition 0.000 claims 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 201000009941 intracranial hypertension Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
- 0 CCc(nc1*C2)nc(N)c1N=C2C(C(*)O)O Chemical compound CCc(nc1*C2)nc(N)c1N=C2C(C(*)O)O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14162727.3A EP2926805B1 (en) | 2014-03-31 | 2014-03-31 | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |
| EP14162727.3 | 2014-03-31 | ||
| PCT/EP2015/056824 WO2015150294A1 (en) | 2014-03-31 | 2015-03-30 | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019123306A Division JP6879582B2 (ja) | 2014-03-31 | 2019-07-02 | ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509623A JP2017509623A (ja) | 2017-04-06 |
| JP2017509623A5 true JP2017509623A5 (enExample) | 2018-05-10 |
| JP6552515B2 JP6552515B2 (ja) | 2019-07-31 |
Family
ID=50389975
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556270A Active JP6552515B2 (ja) | 2014-03-31 | 2015-03-30 | ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 |
| JP2019123306A Active JP6879582B2 (ja) | 2014-03-31 | 2019-07-02 | ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 |
| JP2021072278A Active JP7178731B2 (ja) | 2014-03-31 | 2021-04-22 | ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019123306A Active JP6879582B2 (ja) | 2014-03-31 | 2019-07-02 | ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 |
| JP2021072278A Active JP7178731B2 (ja) | 2014-03-31 | 2021-04-22 | ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US9895372B2 (enExample) |
| EP (2) | EP2926805B1 (enExample) |
| JP (3) | JP6552515B2 (enExample) |
| KR (1) | KR102374500B1 (enExample) |
| CN (2) | CN106572976A (enExample) |
| AU (2) | AU2015239736B2 (enExample) |
| CA (1) | CA2938267C (enExample) |
| CL (1) | CL2016002463A1 (enExample) |
| CY (1) | CY1117881T1 (enExample) |
| DK (1) | DK2926805T3 (enExample) |
| ES (1) | ES2586945T3 (enExample) |
| HR (1) | HRP20160802T1 (enExample) |
| HU (1) | HUE030221T2 (enExample) |
| IL (1) | IL248090B (enExample) |
| MX (1) | MX377919B (enExample) |
| MY (1) | MY180844A (enExample) |
| PE (1) | PE20161253A1 (enExample) |
| PH (1) | PH12016501519A1 (enExample) |
| PL (1) | PL2926805T3 (enExample) |
| PT (1) | PT2926805T (enExample) |
| RS (1) | RS54973B1 (enExample) |
| RU (1) | RU2694368C2 (enExample) |
| SA (1) | SA516371933B1 (enExample) |
| SG (1) | SG11201606151SA (enExample) |
| SI (1) | SI2926805T1 (enExample) |
| SM (1) | SMT201600246B (enExample) |
| WO (1) | WO2015150294A1 (enExample) |
| ZA (1) | ZA201605271B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101927114B1 (ko) | 2014-02-07 | 2018-12-10 | 엑시테라 파마슈티컬스 인코퍼레이티드 | 치료 화합물 및 조성물 |
| SI2926805T1 (sl) | 2014-03-31 | 2016-09-30 | Vasopharm Gmbh | Trdni farmacevtski sestavki, obsegajoči biopterinske derivate in uporabe takšnih sestavkov |
| JP2016168783A (ja) * | 2015-03-13 | 2016-09-23 | 株式会社東芝 | 記録装置、記録方法、及び記録媒体 |
| US12171766B2 (en) | 2021-12-03 | 2024-12-24 | Verinos Operations Gmbh | Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury |
| CA3073957A1 (en) * | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | Pharmaceutical compositions comprising sepiapterin and uses thereof |
| JP6565103B2 (ja) * | 2017-09-06 | 2019-08-28 | 株式会社昭和冷凍プラント | 香気成分含有水溶液を含む液状製品の製造方法 |
| PT4034122T (pt) * | 2019-09-25 | 2025-09-18 | Ptc Therapeutics Mp Inc | Métodos de tratamento de hiperfenilalaninemia |
| WO2023099013A1 (en) | 2021-12-03 | 2023-06-08 | Verinos Operations Gmbh | Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury |
| EP4539850A1 (en) | 2022-05-06 | 2025-04-23 | VeriNOS operations GmbH | Methods of treating patients suffering from a disease condition or disorder that is associated with an increased glutamate level |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922713A (en) * | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
| EP0906913B1 (de) | 1997-10-06 | 2001-05-23 | Ernst Werner | Pteridinderivate als NO Synthase-Hemmer |
| US6803046B2 (en) * | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
| WO2005037286A1 (en) * | 2003-03-25 | 2005-04-28 | Vasopharm Biotech Gmbh | Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia |
| JP2007536210A (ja) * | 2003-11-17 | 2007-12-13 | メルック・エプロバ・アクチエンゲゼルシヤフト | （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形 |
| US20080207624A1 (en) * | 2004-05-11 | 2008-08-28 | Osamu Sugita | Therapeutic Agent for Bh4-Responsive Hyperphenylalaninemia |
| SE0401826D0 (sv) | 2004-07-09 | 2004-07-09 | Trimble Ab | Method of preparing a winding for an n-phase motor |
| AU2005306686B2 (en) * | 2004-11-17 | 2011-06-02 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
| EP1669355A1 (en) * | 2004-12-02 | 2006-06-14 | Vasopharm Biotech GmbH | Aminotetrahydropteridines and processes for manufacture thereof |
| DK2139485T3 (da) * | 2007-04-11 | 2013-01-21 | Biomarin Pharm Inc | Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling |
| WO2008128576A2 (de) | 2007-04-24 | 2008-10-30 | Osram Gesellschaft mit beschränkter Haftung | Schaltungsanordnung zur zündung und zum betrieb einer entladungslampe |
| ES2736730T3 (es) * | 2008-08-12 | 2020-01-07 | Orpha Swiss Gmbh | Forma de administración farmacéutica que contiene tetrahidrobiopterina |
| WO2012117362A1 (en) | 2011-03-01 | 2012-09-07 | Rubicon Research Private Limited | Stable compositions of tetrahydrobiopterin |
| US9006289B2 (en) * | 2011-08-30 | 2015-04-14 | Fresenius Kabi Usa, Llc | Levothyroxine formulations |
| SI2926805T1 (sl) | 2014-03-31 | 2016-09-30 | Vasopharm Gmbh | Trdni farmacevtski sestavki, obsegajoči biopterinske derivate in uporabe takšnih sestavkov |
-
2014
- 2014-03-31 SI SI201430042A patent/SI2926805T1/sl unknown
- 2014-03-31 HU HUE14162727A patent/HUE030221T2/en unknown
- 2014-03-31 PT PT141627273T patent/PT2926805T/pt unknown
- 2014-03-31 EP EP14162727.3A patent/EP2926805B1/en active Active
- 2014-03-31 RS RS20160595A patent/RS54973B1/sr unknown
- 2014-03-31 ES ES14162727.3T patent/ES2586945T3/es active Active
- 2014-03-31 PL PL14162727.3T patent/PL2926805T3/pl unknown
- 2014-03-31 DK DK14162727.3T patent/DK2926805T3/en active
-
2015
- 2015-03-30 CN CN201580017915.6A patent/CN106572976A/zh active Pending
- 2015-03-30 PE PE2016001818A patent/PE20161253A1/es unknown
- 2015-03-30 RU RU2016141449A patent/RU2694368C2/ru active
- 2015-03-30 JP JP2016556270A patent/JP6552515B2/ja active Active
- 2015-03-30 SG SG11201606151SA patent/SG11201606151SA/en unknown
- 2015-03-30 EP EP15715697.7A patent/EP3125864A1/en not_active Withdrawn
- 2015-03-30 US US14/913,665 patent/US9895372B2/en active Active
- 2015-03-30 MX MX2016012784A patent/MX377919B/es unknown
- 2015-03-30 MY MYPI2016702995A patent/MY180844A/en unknown
- 2015-03-30 CA CA2938267A patent/CA2938267C/en active Active
- 2015-03-30 WO PCT/EP2015/056824 patent/WO2015150294A1/en not_active Ceased
- 2015-03-30 KR KR1020167025896A patent/KR102374500B1/ko active Active
- 2015-03-30 CN CN202110640860.1A patent/CN113521017A/zh active Pending
- 2015-03-30 AU AU2015239736A patent/AU2015239736B2/en active Active
-
2016
- 2016-07-06 HR HRP20160802TT patent/HRP20160802T1/hr unknown
- 2016-07-26 SM SM201600246T patent/SMT201600246B/it unknown
- 2016-07-29 ZA ZA2016/05271A patent/ZA201605271B/en unknown
- 2016-08-01 PH PH12016501519A patent/PH12016501519A1/en unknown
- 2016-08-04 CY CY20161100768T patent/CY1117881T1/el unknown
- 2016-09-27 IL IL24809016A patent/IL248090B/en active IP Right Grant
- 2016-09-27 SA SA516371933A patent/SA516371933B1/ar unknown
- 2016-09-29 CL CL2016002463A patent/CL2016002463A1/es unknown
-
2017
- 2017-05-02 US US15/584,890 patent/US10016431B2/en active Active
-
2018
- 2018-06-08 US US16/003,374 patent/US10493075B2/en active Active
-
2019
- 2019-07-02 JP JP2019123306A patent/JP6879582B2/ja active Active
- 2019-10-21 US US16/659,401 patent/US10925877B2/en active Active
-
2020
- 2020-06-12 AU AU2020203880A patent/AU2020203880B2/en active Active
-
2021
- 2021-01-20 US US17/153,749 patent/US11717522B2/en active Active
- 2021-04-22 JP JP2021072278A patent/JP7178731B2/ja active Active
-
2023
- 2023-07-20 US US18/224,515 patent/US12458644B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509623A5 (enExample) | ||
| RU2016141449A (ru) | Твердые фармацевтические композиции, содержащие производные биоптерина, и способы применения таких композиций | |
| JP2013528600A5 (enExample) | ||
| MX2016006197A (es) | Formulaciones de compuestos de azaindol. | |
| JP2017128569A5 (enExample) | ||
| RU2015118581A (ru) | Лиофилизированные препараты мелфалана флуфенамида | |
| BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| EA201291348A1 (ru) | Активаторы растворимой гуанилатциклазы | |
| BR112014029016A8 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| JP2015511609A5 (enExample) | ||
| JP2015535243A5 (enExample) | ||
| RU2016145057A (ru) | Получение тетрациклического соединения, содержащегося в высокой дозе | |
| JP2016512210A5 (enExample) | ||
| RU2017123880A (ru) | Антагонисты миостатина или активина для лечения саркопении | |
| FI3377534T3 (fi) | Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää | |
| JP2015505816A (ja) | Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与 | |
| AR077436A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables. | |
| JP2019521102A5 (enExample) | ||
| JP2013500977A5 (enExample) | ||
| HRP20200196T1 (hr) | Fiziološki balansirane injektabilne formulacije fosnetupitanta | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| MX2021012684A (es) | Composiciones farmaceuticas estables y conservadas de bilastina. | |
| JP2018537514A5 (enExample) | ||
| BR112015018144A8 (pt) | composição de emulsão água/óleo farmacêutica estável com gotículas de óleo manométricas, método para fazer a mesma e alta dose única de clopidogrel usada para tratar um paciente | |
| FI3554474T3 (fi) | Mikafungiinikoostumuksia |